title: Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
abstract: The goal of the Malaria Vaccine Program at the Walter Reed Army Institute of Research (WRAIR) is to develop a licensed multi-antigen, multi-stage vaccine against Plasmodium falciparum able to prevent all symptomatic manifestations of malaria by preventing parasitemia. A secondary goal is to limit disease in vaccinees that do develop malaria. Malaria prevention will be achieved by inducing humoral and cellular immunity against the pre-erythrocytic circumsporozoite protein (CSP) and the liver stage antigen-1 (LSA-1). The strategy to limit disease will target immune responses against one or more blood stage antigens, merozoite surface protein-1 (MSP-1) and apical merozoite antigen-1 (AMA-1). The induction of T- and B-cell memory to achieve a sustained vaccine response may additionally require immunization with an adenovirus vector such as adenovirus serotype 35. RTS,S, a CSP-derived antigen developed by GlaxoSmithKline Biologicals in collaboration with the Walter Reed Army Institute of Research over the past 17 years, is the cornerstone of our program. RTS,S formulated in AS02A (a GSK proprietary formulation) is the only vaccine candidate shown in field trials to prevent malaria and, in one instance, to limit disease severity. Our vaccine development plan requires proof of an individual antigen's efficacy in a Phase 2 laboratory challenge or field trial prior to its integration into an RTS,S-based, multi-antigen vaccine. Progress has been accelerated through extensive partnerships with industrial, academic, governmental, and non-governmental organizations. Recent safety, immunogenicity, and efficacy trials in the US and Africa are presented, as well as plans for the development of a multi-antigen vaccine.
authors.affiliation: Walter Reed Army Institute of Research, Department of Immunology, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA. donald.heppner@na.amedd.army.mil
authors.forename: D Gray
authors.initials: DG
authors.lastname: Heppner
authors.forename: Kent E
authors.initials: KE
authors.lastname: Kester
authors.forename: Christian F
authors.initials: CF
authors.lastname: Ockenhouse
authors.forename: Nadia
authors.initials: N
authors.lastname: Tornieporth
authors.forename: Opokua
authors.initials: O
authors.lastname: Ofori
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Lyon
authors.forename: V Ann
authors.initials: VA
authors.lastname: Stewart
authors.forename: Patrice
authors.initials: P
authors.lastname: Dubois
authors.forename: David E
authors.initials: DE
authors.lastname: Lanar
authors.forename: Urszula
authors.initials: U
authors.lastname: Krzych
authors.forename: Philippe
authors.initials: P
authors.lastname: Moris
authors.forename: Evelina
authors.initials: E
authors.lastname: Angov
authors.forename: James F
authors.initials: JF
authors.lastname: Cummings
authors.forename: Amanda
authors.initials: A
authors.lastname: Leach
authors.forename: B Ted
authors.initials: BT
authors.lastname: Hall
authors.forename: Sheetij
authors.initials: S
authors.lastname: Dutta
authors.forename: Robert
authors.initials: R
authors.lastname: Schwenk
authors.forename: Collette
authors.initials: C
authors.lastname: Hillier
authors.forename: Arnoldo
authors.initials: A
authors.lastname: Barbosa
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Ware
authors.forename: Lalitha
authors.initials: L
authors.lastname: Nair
authors.forename: Christian A
authors.initials: CA
authors.lastname: Darko
authors.forename: Mark R
authors.initials: MR
authors.lastname: Withers
authors.forename: Bernhards
authors.initials: B
authors.lastname: Ogutu
authors.forename: Mark E
authors.initials: ME
authors.lastname: Polhemus
authors.forename: Mark
authors.initials: M
authors.lastname: Fukuda
authors.forename: Sathit
authors.initials: S
authors.lastname: Pichyangkul
authors.forename: Montip
authors.initials: M
authors.lastname: Gettyacamin
authors.forename: Carter
authors.initials: C
authors.lastname: Diggs
authors.forename: Lorraine
authors.initials: L
authors.lastname: Soisson
authors.forename: Jessica
authors.initials: J
authors.lastname: Milman
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Dubois
authors.forename: Nathalie
authors.initials: N
authors.lastname: Garçon
authors.forename: Kathryn
authors.initials: K
authors.lastname: Tucker
authors.forename: Janet
authors.initials: J
authors.lastname: Wittes
authors.forename: Christopher V
authors.initials: CV
authors.lastname: Plowe
authors.forename: Mahamadou A
authors.initials: MA
authors.lastname: Thera
authors.forename: Ogobara K
authors.initials: OK
authors.lastname: Duombo
authors.forename: Maria G
authors.initials: MG
authors.lastname: Pau
authors.forename: Jaap
authors.initials: J
authors.lastname: Goudsmit
authors.forename: W Ripley
authors.initials: WR
authors.lastname: Ballou
authors.forename: Joe
authors.initials: J
authors.lastname: Cohen
mesh_terms: D000047:Academies and Institutes; D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D002986:Clinical Trials as Topic; D005822:Genetic Vectors; D006801:Humans; D017780:Malaria Vaccines / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification* / Q000494:pharmacology; D016778:Malaria, Falciparum / Q000517:prevention & control; D008565:Membrane Proteins / Q000235:genetics / Q000276:immunology; D020066:Merozoite Surface Protein 1 / Q000235:genetics / Q000276:immunology; D010963:Plasmodium falciparum / Q000235:genetics / Q000276:immunology*; D015800:Protozoan Proteins / Q000235:genetics / Q000276:immunology; D014481:United States
chemical_list: D000953:Antigens, Protozoan; D017780:Malaria Vaccines; D008565:Membrane Proteins; D020066:Merozoite Surface Protein 1; D015800:Protozoan Proteins; C493155:RTS,S-AS02A vaccine; C090077:apical membrane antigen I, Plasmodium; C067302:liver stage-specific antigen, Plasmodium